{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:00:47Z","timestamp":1780560047685,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ejca.2020.04.022","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T12:08:22Z","timestamp":1590235702000},"page":"9-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node\u2013positive melanoma without the need for completion lymph node dissection"],"prefix":"10.1016","volume":"134","author":[{"given":"Dani\u00eblle","family":"Verver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rekkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"van Klaveren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.J.","family":"van Akkooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry W.E.M.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Testori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara L.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid A.M.","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Keilholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"Gr\u00fcnhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.04.022_bib1","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2020.04.022_bib2","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.022_bib3","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.04.022_bib4","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.04.022_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.9501","article-title":"Final analysis of DECOG-SLT trial: survival outcomes of complete lymph node dissection in melanoma patients with positive sentinel node","volume":"36","author":"Leiter","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.022_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.02306","article-title":"Final analysis of DeCOG-SLT trial: No survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node","author":"Leiter","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.022_bib7","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.04.022_bib8","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.04.022_bib9","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.04.022_bib10","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.04.022_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2018.02.022","article-title":"Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations","volume":"96","author":"Verver","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2020.04.022_bib12","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1200\/JCO.2007.15.4179","article-title":"Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma","volume":"26","author":"Gershenwald","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.022_bib13","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1200\/JCO.2004.01.012","article-title":"Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma","volume":"22","author":"Lee","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.022_bib14","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1200\/JCO.2010.30.9567","article-title":"Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes","volume":"28","author":"Murali","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.022_bib15","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2010.31.6760","article-title":"Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria","volume":"29","author":"van der Ploeg","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.022_bib16","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/bjs.10475","article-title":"Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma","volume":"104","author":"Oude Ophuis","year":"2017","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejca.2020.04.022_bib17","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ejso.2016.05.012","article-title":"The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - an EORTC Melanoma Group study","volume":"42","author":"Oude Ophuis","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2020.04.022_bib18","first-page":"370","article-title":"American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine","volume":"66","author":"Kattan","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2020.04.022_bib19","first-page":"1","article-title":"MICE: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Software"},{"key":"10.1016\/j.ejca.2020.04.022_bib20","series-title":"Clinical prediction models","author":"Steyerberg","year":"2009"},{"key":"10.1016\/j.ejca.2020.04.022_bib21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2020.04.022_bib22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jclinepi.2015.04.005","article-title":"Prediction models need appropriate internal, internal-external, and external validation","volume":"69","author":"Steyerberg","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2020.04.022_bib23","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/SLA.0b013e31818fefe0","article-title":"Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes","volume":"248","author":"van Akkooi","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2020.04.022_bib24","article-title":"Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III\/IV melanoma: updated results from a phase III trial (CheckMate 238)","volume":"36","author":"Jeffrey","year":"2018","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.ejca.2020.04.022_bib25","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.18.01219","article-title":"Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma","volume":"36","author":"Hauschild","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.022_bib26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2019.07.004","article-title":"Melanoma-specific survival in patients with positive sentinel lymph nodes: relevance of sentinel tumor burden","volume":"123","author":"Satzger","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2020.04.022_bib27","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/ijc.25747","article-title":"Age as a key factor influencing metastasizing patterns and disease-specific survival after sentinel lymph node biopsy for cutaneous melanoma","volume":"129","author":"Kretschmer","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2020.04.022_bib28","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.2011.41.3799","article-title":"Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma","volume":"30","author":"Eggermont","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.022_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2015.11.014","article-title":"Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: ulceration of primary is key determinant for IFN-sensitivity","volume":"55","author":"Eggermont","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2020.04.022_bib30","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrclinonc.2017.88","article-title":"Monitoring immune-checkpoint blockade: response evaluation and biomarker development","volume":"14","author":"Nishino","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.022_bib31","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.ejso.2007.07.197","article-title":"Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institution","volume":"34","author":"Roulin","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2020.04.022_bib32","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ijsu.2020.01.146","article-title":"Does the time interval between sentinel lymph node biopsy and completion lymph node dissection affect outcome in malignant melanoma? A retrospective cohort study","volume":"75","author":"Richtig","year":"2020","journal-title":"Int J Surg"},{"key":"10.1016\/j.ejca.2020.04.022_bib33","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/jso.25444","article-title":"Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit","volume":"119","author":"Klemen","year":"2019","journal-title":"J Surg Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:27:15Z","timestamp":1760732835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920302252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":33,"alternative-id":["S0959804920302252"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.04.022","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node\u2013positive melanoma without the need for completion lymph node dissection","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}